FUSED HETEROCYCLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF

WIPO Patent Application WO/2005/085265

A1

A nitrogenous fused-ring derivative represented by the following general formula (I), a pharmacologically acceptable salt thereof, or a prodrug of either. They have human SGLT inhibitory activity and are useful as a preventive or therapeutic agent for diseases attributable to hyperglycemia, such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, and obesity. [In the formula (I), one of R¹ and R⁴ represents a group represented by the following general formula (S) (wherein R⁵ and R⁶ each represents H, OH, halogeno, etc.; Q represents alkylene, etc.; and ring A represents aryl, etc.) and the other represents H, OH, amino, etc.; R² and R³ each represents H, OH, amino, halogeno, optionally substituted alkyl, etc.; A¹ represents O, S, etc.; A² represents CH or N; and G represents a group represented by the following general formula (G-1) (wherein E¹ is H, F, or OH and E² represents H, F, methyl, etc.) or the group represented by the following general formula (G-2).]

FUSHIMI NOBUHIKO (JP)
FUJIKURA HIDEKI (JP)
ISAJI MASAYUKI (JP)

PCT/JP2005/004152

September 15, 2005

March 03, 2005

Click for automatic bibliography generation  

KISSEI PHARMACEUTICAL (JP)
FUSHIMI NOBUHIKO (JP)
FUJIKURA HIDEKI (JP)
ISAJI MASAYUKI (JP)

A61K31/7042; A61P3/04; A61P3/06; A61P3/10; A61P7/10; A61P9/10; A61P9/12; A61P19/06; C07H17/00; (IPC1-7): C07H17/00; A61K31/7042; A61P3/04; A61P3/06; A61P3/10; A61P7/10; A61P9/10; A61P9/12; A61P19/06

WO2003000712A1

2003-01-03

JP2003012686A	2003-01-15
JP2002193948A	2002-07-10
JP2001354568A	2001-12-25
JP2004300102A	2004-10-28
JPH08502721A	1996-03-26

See also references of EP 1724277A4

View/Download PDF      PDF Help

Previous Patent: MOLECULAR SPACER, PRODUCTION METHOD THEREOF AND USES OF SAME ON AN ANALYSIS CHIP WITH MOLECULES OR B...

Next Patent: MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME